Showing 3981-3990 of 9406 results for "".
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P
- Pharma Penalties Total $10.2B Over Two Yearshttps://practicaldermatology.com/news/20120928-pharma_penalties_total_102b_over_two_years/2459727/Pharmaceutical manufacturers have reached a total of 74 settlements, totaling $10.2 billion in financial penalties with federal and state governments between November 2, 2010 and July 18, 2012. That's the conclusion of an updated report from P
- Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.https://practicaldermatology.com/news/20120626-wellness_center_usa_inc_signs_agreement_to_acquire_psoria-shield_inc/2459782/Wellness Center USA Inc.(OTCQB/OTCBB: WCUI), a healthcare and nutraceutical company, signed a share exchange agreement to acquire Psoria-Shield Inc. (PSI), a developer and manufacturer of UV p
- Merz Appoints New Vice President of Medical Dermatologyhttps://practicaldermatology.com/news/20120611-merz_appoints_new_vice_president_of_medical_dermatology/2459786/Merz, Inc. has appointed James P. Hartman as Vice President of Medical Dermatology. In the new role, Hartman will be responsible for the company's Medical and OTC/OTX dermatology business unit, which includes Naftin® (naftifine hydrochloride) and Mede
- Avon Chooses Greenwich, CT Dermatologist to Champion ANEW Brandhttps://practicaldermatology.com/news/avon-chooses-greenwich-conn-dermatologist-to-champion-anew-brand/2458390/Kim Nichols, MD, is now Avon’s new consulting dermatologist. In her role, the Greenwich, Conn.-based dermatologist will help to educate Avon Representatives on the technology behind the
- Estée Lauder's Newest Collection Embraces Gen Yhttps://practicaldermatology.com/news/este-lauders-newest-collection-embraces-gen-y/2458652/Estee Lauder’s latest collection is all about the millennials. Fronted by guest editors Kendall Jenner and Irene Kim, the Estée Edit by Estée Lauder comprises 82 makeup and skincare products. The collection is inspired by Estée&rs
- New Agreement Opens Premier Networks to TeleVox Techhttps://practicaldermatology.com/news/televox-and-premier-inc-announce-national-patient-engagement-agreement/2476115/TeleVox has announced a national group purchasing agreement with Premier, Inc. effective September 1, 2025, permiting Premier members to access negotiated pricing and terms for TeleVox offerings, including Digital Front Door, Appointment Management, Digital Care P
- PPIs, H2RAs Can Increase Psoriasis Risk for Patients With GI Diseaseshttps://practicaldermatology.com/news/ppis-h2ras-can-increase-psoriasis-risk-patients-gi-diseases/2470871/Prolonged use of proton pump inhibitor (PPI) or histamine-2 receptor antagonists (H2RA) is associated with the risk of psoriasis among patients with gastrointestinal diseases, according to a new study published in the Korean Journal of Internal Medicine. The study included 3,662 p
- Promising Pipeline for CSU Optionshttps://practicaldermatology.com/news/promising-pipeline-csu-options/2468488/Cleveland Clinic allergist Dr. David Lang joined Dr. Dawn Merritt and Dr. Brad P. Glick to discuss chronic spontaneous urticaria (CSU) at the 44th Annual Fall Clinical Dermatology Conference and noted that the future is very promising. “Our recent understanding of chronic urticaria has imp
- ADORING 3: Tapinarof Cream Maintains AD Clearance for 80 Days Post-Treatmenthttps://practicaldermatology.com/news/adoring-3-tapinarof-cream-maintains-ad-clearance-80-days-post-treatment/2468482/Results from the ADORING 3 long-term extension study showed that VTAMA® (tapinarof) cream, 1% achieved complete skin clearance in atopic dermatitis (AD) patients as young as two years old, maintaining clear or nearly clear skin for an average of 80 days post-treatment. The 48-week study, p